Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing Into Phase 2 Clinical Development Under Multi Program Collaboration With Neurocrine Biosciences is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program ... Read More
Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2
Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for ... to be selected for clinical development in 2019. Read More
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
We look forward to working with Bioprojet and advancing the development program for TPM ... best-in-class orexin-2 receptor agonist will extend the productive collaboration between Bioprojet ... Read More
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Viking also plans to initiate a Phase 2 trial of oral ... company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist ... Read More
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine Biosciences Successful ... Read More
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and ... Read More
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
The agreement will accelerate the development of this orexin-2 receptor agonist and is ... to working with Bioprojet and advancing the development program for TPM-1116 as part of our growth strategy." ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus